Syncom Formulations (India) Limited
Syncom Formulations Board is scheduled to meet on May 22, 2026, to consider and approve its audited financial results for the quarter and full financial year ended March 31, 2026. This meeting will also include a review of the audit report and financial statements.
May 13 2026 16:05:00
Syncom Formulations India Ltd-$ - 524470 - Board Meeting Intimation for Corporate Announcement U/R 29(1)(A) Of SEBI (LODR) Regulations, 2015 Regarding Intimation Of Holding Board Meeting For Consideration And Approval Of The Standalone And Consolidated Audited Financial Results, As On 31St March, 2026
Syncom Formulations board meeting scheduled for May 22, 2026, at 3:00 P.M. to consider and approve standalone and consolidated audited financial results for the quarter and year ended March 31, 2026.
May 13 2026 16:05:00
Syncom Formulations (India) Limited
Syncom Formulations has successfully acquired a commercial property for Rs. 57.26 crore from HDFC Bank Ltd. This acquisition of the entire 7th Floor, Trade Star, Andheri-Kurla Road, Mumbai, is considered material by the company for operational expansion.
May 04 2026 18:05:00
Syncom Formulations India Ltd-$ - 524470 - Disclosure Under Regulation 30 Of SEBI (LODR) Regulations, 2015 Read With Master SEBI Circular HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 Dated 30Th January, 2026.
Syncom Formulations completed the acquisition of a commercial property, the entire 7th Floor of Trade Star in Andheri, Mumbai. The property was acquired for a total consideration of Rs. 57.26 crore from HDFC Bank Ltd, enhancing the company's operational footprint.
May 04 2026 18:05:00
Syncom Formulations (India) Limited
Syncom Formulations (India) Limited has disclosed its shareholding pattern for Q4 FY26. The promoter and promoter group collectively hold 50.57% of the total 94 crore paid-up equity shares. Public shareholding accounts for 49.43%, reflecting broad ownership distribution.
Apr 16 2026 15:04:00
Read More